Canaccord Genuity Group Lowers Aurora Cannabis (TSE:ACB) Price Target to C$6.50

Aurora Cannabis (TSE:ACB) had its price objective decreased by equities research analysts at Canaccord Genuity Group from C$8.00 to C$6.50 in a research note issued to investors on Friday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 52.94% from the stock’s previous close.

Separately, TD cut their price target on Aurora Cannabis to C$8.00 and set a “buy” rating on the stock in a report on Friday. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Aurora Cannabis has an average rating of “Buy” and an average price target of C$7.67.

Aurora Cannabis Stock Performance

TSE ACB traded down C$0.03 during trading hours on Friday, reaching C$4.25. The company’s stock had a trading volume of 371,398 shares, compared to its average volume of 412,147. The company has a current ratio of 3.06, a quick ratio of 2.48 and a debt-to-equity ratio of 25.02. The business has a 50-day simple moving average of C$4.77 and a 200 day simple moving average of C$5.31. Aurora Cannabis has a 52 week low of C$3.77 and a 52 week high of C$9.33. The stock has a market cap of C$251.29 million, a PE ratio of -2.83 and a beta of 0.17.

Aurora Cannabis (TSE:ACB) last issued its earnings results on Thursday, June 11th. The company reported C($0.99) earnings per share (EPS) for the quarter. Aurora Cannabis had a negative return on equity of 1.15% and a negative net margin of 1.69%.The business had revenue of C$38.01 million during the quarter. Equities research analysts predict that Aurora Cannabis will post -0.22 earnings per share for the current fiscal year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.